Drugs /

citarinostat

Back to Drugs List

Overview

NCI Definition [1]:
An orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, ACY-241 inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibit tumor cell division and induce tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.

Clinical Trials

View Clinical Trials for citarinostat

Citarinostat has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating citarinostat, 2 are phase 1 (2 open).

HLA-A*02 Positive is the most frequent biomarker inclusion criterion for citarinostat clinical trials.

Non-small cell lung carcinoma and smoldering plasma cell myeloma are the most common diseases being investigated in citarinostat clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Citarinostat
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating citarinostat and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cc-96241, hdac-in-2, histone deacetylase inhibitor acy-241, acy-241, histone deacetylase inhibitor acy-241, hdac inhibitor acy-241
Drug Target(s) [2]:
HDAC6
NCIT ID [1]:
C121641

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.